Physician profile
Kenneth W Eckmann
NPI 1982676201
$19,104.56
in general payments reported to CMS, 2019-2025
73 companies · $2,370 in 2025
The $2,370 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $1,558 · 2021: $2,606 · 2022: $3,308 · 2023: $3,713 · 2024: $3,562 · 2025: $2,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,644.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,650.89 | 2021-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $2,412.38 | 2019-2025 | |
| Pfizer INC. | $1,464.00 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,265.37 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Biogen, INC. | $1,208.75 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $1,160.40 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Ucb, INC. | $636.33 | 2019-2024 | Rystiggo |
| Lundbeck LLC | $496.94 | 2020-2025 | Vyepti, Rexulti |
| Amgen INC. | $444.34 | 2019-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $441.72 | 2019-2025 | Rytary, Crexont, Ongentys |
| Acadia Pharmaceuticals INC | $401.00 | 2019-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $374.89 | 2019-2022 | |
| Genentech USA, INC. | $358.16 | 2020-2025 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceutical Holding Company LTD. | $327.26 | 2022 | |
| Emd Serono, INC. | $314.14 | 2019-2024 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Eckmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.